VLVijittra Leardkamolkarn

Vijittra Leardkamolkarn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vijittra Leardkamolkarn has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development of Dengue type-2 virus replicons expressing GFP reporter gene in study of viral RNA replication

    by Vijittra Leardkamolkarn, Wipawan Sirigulpanit, Nunya Chotiwan, Supeecha Kumkate, Claire Y.-H. Huang


  • THE INHIBITORY ACTIONS OF HOUTTUYNIA CORDATA AQUEOUS EXTRACT ON DENGUE VIRUS AND DENGUE-INFECTED CELLS

    by Vijittra Leardkamolkarn, Wipawan Sirigulpanit, Chayakom Phurimsak, Supeecha Kumkate, Lukana Himakoun, Bungorn Sripanidkulchai

    The antiviral activities of Houttuynia cordata (H. cordata) aqueous extract against dengue virus serotype 2 (DEN-2), strain 16681, were evaluated in this study. The results showed that pre- and post-incubation of H. cordata extract (10–100 µg/mL) with HepG2 cells significantly reduced intracellular DEN-2 RNA production correlating with the decrease in dengue protein expression. In the direct blocking mode, the extract bound with DEN-2 and strongly inhibited the intracellular viral RNA replication with an effective dose (EC50) of 0.8 µg/mL. Concentrations as low as 10–40 µg/mL of H. cordata extract also exhibited protective effect on virion release from infected LLC-MK2 cells. High-performance liquid chromatography analysis of H. cordata extract indicated that hyperoside was the predominant bioactive compound, and was likely to play a role in this inhibition. The extract was also shown to have no genotoxic effect on human blood cells. PRACTICAL APPLICATIONS Houttuynia cordata is recognized as medicinal vegetable consumed by people in East and Southeast Asia. It has multilateral activities in health promotion and regulation of inflammatory reactions induced by several pathogens. Dengue viral infection is a global health problem since licensed vaccines or specific antiviral drug treatments are not yet available. The current study provides scientific data to support the phytomedicinal properties of H. cordata aqueous extract on anti-dengue virus in three modes of action (prevention, treatment and virucidal). A major constituent in the extract, hyperoside, seems to be the bioactive compound effectively acting against dengue infection. H. cordata aqueous extract was shown to be nontoxic and hyperoside may be considered a lead compound possessing drug potential for further development.


  • Open Access

    Characterization of Recombinant Dengue-2 Virus Derived from a Single Nucleotide Substitution in the 5′ Noncoding Region

    by Vijittra Leardkamolkarn, Wipawan Sirigulpanit, Richard M. Kinney

    Variants of wild-type dengue serotype 2 (DEN-2) virus containing nucleotide substitutions at positions 14, 15, or 57 in the5′NCR were constructed by PCR-mediated site-directed mutagenesis. All three viruses containing a single point substitution demonstrated attenuation phenotype as evidenced by decreases replication and plaque size in cell culture assay. All three variants were less neurovirulent in newborn mice compared to the wild type. The mutants were immunogenic in adult mice immunogenicity and maintained stable replication characteristics following passage in mice. The variant viruses were competent for replication inAedes aegypimosquito vector, albeit at lower levels of infection and dissemination in the mosquito than the wild-type Den-2 16681 virus. Although all of the viruses, including the wild type, were found transmissible in mosquito life cycles, they were found subsequentially decreased in efficiency of infection, transmission, and dissemination rates along the mosquito generations and all of them remained genetically stable.


    • 16 October 2009
      • Vol. 10  (4) , 695-8

    Pharmacological activity of Kaempferia parviflora extract against human bile duct cancer cell lines.

    by Vijittra Leardkamolkarn, Sunida Tiamyuyen, Bung-Orn Sripanidkulchai

    A crude ethanol extract of Kaemperia parviflora Wall. Ex Baker and a purified compound, 5,7,4-trimethoxyflavone (KP.8.10), were evaluated for pharmacological effects on human cholangiocarcinoma cell lines (HuCCA-1 and RMCCA-1). The cells were incubated with various concentrations of extract for various time periods and metabolic activity (MTT assay) was assessed for cell viability. The results showed a dose-dependent effect of both crude ethanol extract and the pure compound. CC50s for the crude extract on HuCCA-1 and RMCCA-1 cells were 46.1 microg/ml and 62.0 microg/ml, respectively. Values for the pure compound could not be determined because of solubility problems. Interestingly, K. parviflora ethanol extract and KP.8.10 at low concentrations (10-20 microg/ml and 2.5-5 microg/ml, respectively) markedly reduced rhHGF-induced invasion by HuCCA-1 and RMCCA-1 cells across matrix-coated transwell plates. Higher concentrations of K. parviflora ethanol extract (60 and 80 microg/ml) and KP.8.10 (20 microg /ml) dramatically changed the cellular morphology and caused death in both cell types. KP.8.10 further exhibited progressive action via caspase-3 mitochondrial enzyme activation, enhancing cellular toxicity in a time-dose dependent fashion. Therefore, 5,7,4-trimethoxyflavone appeared to be a bioactive component of K. parviflora extract capable of exerting anti-cancer action. The results suggested a benefit of this edible plant in prevention and treatment of cholangiocarcinoma.


  • Open Access

    Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1

    by Urai Pongchairerk, Jun-Lin Guan, Vijittra Leardkamolkarn

    Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1


  • Open Access

    Upregulation of tumour associated antigen RCAS1 is implicated in high stages of colorectal cancer

    by K Leelawat, T Watanabe, M Nakajima, S Tujinda, C Suthipintawong, V Leardkamolkarn

    Background: RCAS1 (receptor binding cancer antigen expressed on SiSo cells) is a tumour associated antigen. It is involved in immune evasion by tumour cells, by binding to receptors on cells involved in the immune response, such as T cells and natural killer cells, and inducing apoptosis. High expression of RCAS1 has been demonstrated immunohistochemically in tumours of the cervix, breast, lung, and stomach; however, the expression of RCAS1 has never been investigated in colorectal cancer. Aims: To investigate the expression of RCAS1 in colorectal cancer and identify at which stages of colorectal carcinogenesis it is expressed. Methods: Sixty surgically resected colorectal cancer specimens obtained from Rajavithi Hospital, Bangkok, Thailand were studied. RCAS1 expression was detected immunohistochemically using monoclonal anti–RCAS1 antibody. RCAS1 mRNA expression was also investigated by reverse transcription polymerase chain reaction in the freshly isolated tissues, and serum RCAS1 was measured by enzyme linked immunosorbent assay. Results: Staining for the RCAS1 protein was intense in high stages of colorectal cancer, but weak in normal tissues. The RCAS1 mRNA results correlated with the immunohistochemistry results. Positive serum RCAS1 concentrations were found in 10 of 18 patients with stage II disease and 12 of 32 with stage III and IV, but not in patients with stage I disease. All lymph node and liver metastases showed high expression of RCAS1 protein. Conclusions: RCAS1 appears to be upregulated in high stages of colorectal cancer, both in the serum and the tissue. RCAS1 expression might be a useful additional criterion for staging this cancer.